ES2909885T3 - Inhibidores de la calicreína plasmática - Google Patents
Inhibidores de la calicreína plasmática Download PDFInfo
- Publication number
- ES2909885T3 ES2909885T3 ES17166782T ES17166782T ES2909885T3 ES 2909885 T3 ES2909885 T3 ES 2909885T3 ES 17166782 T ES17166782 T ES 17166782T ES 17166782 T ES17166782 T ES 17166782T ES 2909885 T3 ES2909885 T3 ES 2909885T3
- Authority
- ES
- Spain
- Prior art keywords
- mmol
- optionally substituted
- alkyl
- ylmethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000113 Plasma Kallikrein Proteins 0.000 title claims description 47
- 102000003827 Plasma Kallikrein Human genes 0.000 title claims description 45
- 229940127379 Kallikrein Inhibitors Drugs 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 122
- 239000000203 mixture Substances 0.000 claims abstract description 104
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 103
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 65
- 125000001424 substituent group Chemical group 0.000 claims abstract description 57
- 125000003118 aryl group Chemical group 0.000 claims abstract description 43
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 28
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 26
- MVXVYAKCVDQRLW-UHFFFAOYSA-N azain Natural products C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 claims abstract description 24
- 125000005843 halogen group Chemical group 0.000 claims abstract description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract description 15
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 15
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000012453 solvate Substances 0.000 claims abstract description 14
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 11
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract description 10
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 9
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000010290 biphenyl Nutrition 0.000 claims abstract description 8
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 claims abstract description 8
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 8
- 229930195734 saturated hydrocarbon Natural products 0.000 claims abstract description 8
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract description 7
- 125000002619 bicyclic group Chemical group 0.000 claims abstract description 7
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 7
- 239000004305 biphenyl Chemical group 0.000 claims abstract description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 5
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical class N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000005058 1,8-naphthyridines Chemical class 0.000 claims abstract description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims abstract description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims abstract description 4
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000003248 quinolines Chemical class 0.000 claims abstract description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 3
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 claims abstract 3
- 150000003252 quinoxalines Chemical class 0.000 claims abstract 3
- 150000005057 1,7-naphthyridines Chemical class 0.000 claims abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 17
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 13
- 201000011190 diabetic macular edema Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 230000008728 vascular permeability Effects 0.000 claims description 9
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 230000002207 retinal effect Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- GDAXJBDYNVDMDF-UHFFFAOYSA-N 1,2,4-benzotriazine Chemical class N1=NC=NC2=CC=CC=C21 GDAXJBDYNVDMDF-UHFFFAOYSA-N 0.000 claims description 3
- 208000001953 Hypotension Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 3
- 230000036543 hypotension Effects 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000004304 visual acuity Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 150000005258 1H-pyrrolo(2,3-b)pyridines Chemical class 0.000 abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 274
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 231
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 179
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 134
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 130
- 235000019439 ethyl acetate Nutrition 0.000 description 126
- 239000007787 solid Substances 0.000 description 99
- 239000000243 solution Substances 0.000 description 95
- 239000011541 reaction mixture Substances 0.000 description 86
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 77
- 239000012267 brine Substances 0.000 description 75
- 239000000377 silicon dioxide Substances 0.000 description 64
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 58
- -1 indole amides Chemical class 0.000 description 56
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 54
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 54
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 52
- 238000006243 chemical reaction Methods 0.000 description 50
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 49
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 48
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 239000007832 Na2SO4 Substances 0.000 description 45
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 45
- 229910052938 sodium sulfate Inorganic materials 0.000 description 45
- 235000011152 sodium sulphate Nutrition 0.000 description 45
- 239000002904 solvent Substances 0.000 description 42
- 238000003818 flash chromatography Methods 0.000 description 40
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 38
- 238000005160 1H NMR spectroscopy Methods 0.000 description 36
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 36
- 238000004587 chromatography analysis Methods 0.000 description 36
- 239000010410 layer Substances 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 34
- 238000003756 stirring Methods 0.000 description 34
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 33
- 239000002253 acid Substances 0.000 description 32
- 239000000047 product Substances 0.000 description 29
- 239000012044 organic layer Substances 0.000 description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 26
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 26
- 235000019341 magnesium sulphate Nutrition 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 22
- 239000012043 crude product Substances 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 22
- YUHZIUAREWNXJT-UHFFFAOYSA-N (2-fluoropyridin-3-yl)boronic acid Chemical class OB(O)C1=CC=CN=C1F YUHZIUAREWNXJT-UHFFFAOYSA-N 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 20
- 239000003921 oil Substances 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- LWDVTRXNUGVQES-UHFFFAOYSA-N 6-(aminomethyl)isoquinolin-1-amine Chemical compound NC1=NC=CC2=CC(CN)=CC=C21 LWDVTRXNUGVQES-UHFFFAOYSA-N 0.000 description 18
- 125000006239 protecting group Chemical group 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 239000007821 HATU Substances 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 239000012299 nitrogen atmosphere Substances 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 9
- 239000012223 aqueous fraction Substances 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 239000013058 crude material Substances 0.000 description 9
- 239000012458 free base Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052721 tungsten Inorganic materials 0.000 description 8
- 102100038297 Kallikrein-1 Human genes 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- AKICKQUUHMJAPD-UHFFFAOYSA-N 1-[[4-(chloromethyl)phenyl]methyl]-4-methylpyrazole Chemical compound Cc1cnn(Cc2ccc(CCl)cc2)c1 AKICKQUUHMJAPD-UHFFFAOYSA-N 0.000 description 6
- UVUGVZJMKMGPPT-UHFFFAOYSA-N 1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound OC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1C(F)(F)F UVUGVZJMKMGPPT-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 description 6
- 102100035792 Kininogen-1 Human genes 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 229940126155 plasma kallikrein inhibitor Drugs 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 108010093008 Kinins Proteins 0.000 description 5
- 102000002397 Kinins Human genes 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- HSHMTRLVTQNRRC-UHFFFAOYSA-N [4-[(4-methylpyrazol-1-yl)methyl]phenyl]methanol Chemical compound C1=C(C)C=NN1CC1=CC=C(CO)C=C1 HSHMTRLVTQNRRC-UHFFFAOYSA-N 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 5
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 238000012437 strong cation exchange chromatography Methods 0.000 description 5
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- OINHGEBQNPOQFY-UHFFFAOYSA-N 1-[[4-(hydroxymethyl)phenyl]methyl]pyridin-2-one Chemical compound C1=CC(CO)=CC=C1CN1C(=O)C=CC=C1 OINHGEBQNPOQFY-UHFFFAOYSA-N 0.000 description 4
- RLSJQNBYFSVJQO-UHFFFAOYSA-N 1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1CC(C=C1)=CC=C1CN1C(=O)C=CC=C1 RLSJQNBYFSVJQO-UHFFFAOYSA-N 0.000 description 4
- GRVARXIAOACIRT-UHFFFAOYSA-N 1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-morpholin-4-ylpyrazole-4-carboxylic acid Chemical compound Cc1cnn(Cc2ccc(Cn3cc(C(O)=O)c(n3)N3CCOCC3)cc2)c1 GRVARXIAOACIRT-UHFFFAOYSA-N 0.000 description 4
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- OIVHKYLWRHFIMZ-UHFFFAOYSA-N 3-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound Cc1cnn(Cc2ccc(Cn3cc(C(O)=O)c(n3)-c3c(C)noc3C)cc2)c1 OIVHKYLWRHFIMZ-UHFFFAOYSA-N 0.000 description 4
- AKPRXDPKAOMICH-UHFFFAOYSA-N 3-cyano-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound Cc1cnn(Cc2ccc(Cn3cc(C(O)=O)c(n3)C#N)cc2)c1 AKPRXDPKAOMICH-UHFFFAOYSA-N 0.000 description 4
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 4
- QRXZNFSVRLDKPE-UHFFFAOYSA-N 5-(chloromethyl)-2-fluoropyridine Chemical compound FC1=CC=C(CCl)C=N1 QRXZNFSVRLDKPE-UHFFFAOYSA-N 0.000 description 4
- LAXWAYHNIVBBPC-UHFFFAOYSA-N 6-(aminomethyl)isoquinolin-1-amine;dihydrochloride Chemical compound Cl.Cl.NC1=NC=CC2=CC(CN)=CC=C21 LAXWAYHNIVBBPC-UHFFFAOYSA-N 0.000 description 4
- ZQLGDZJSXZXKLU-UHFFFAOYSA-N 6-(aminomethyl)isoquinolin-1-amine;hydrochloride Chemical compound Cl.NC1=NC=CC2=CC(CN)=CC=C21 ZQLGDZJSXZXKLU-UHFFFAOYSA-N 0.000 description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- OGALXJIOJZXBBP-UHFFFAOYSA-N [4-(chloromethyl)phenyl]methanol Chemical compound OCC1=CC=C(CCl)C=C1 OGALXJIOJZXBBP-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RZQRRUODDCZJOA-UHFFFAOYSA-N (6-chloro-5-methoxypyridin-3-yl)methanol Chemical compound COC1=CC(CO)=CN=C1Cl RZQRRUODDCZJOA-UHFFFAOYSA-N 0.000 description 3
- NOBSMYQUCFGMEL-UHFFFAOYSA-N 1-[(6-ethoxypyridin-3-yl)methyl]-3-[(2-methoxyacetyl)amino]pyrazole-4-carboxylic acid Chemical compound CCOc1ccc(Cn2cc(C(O)=O)c(NC(=O)COC)n2)cn1 NOBSMYQUCFGMEL-UHFFFAOYSA-N 0.000 description 3
- HOSLEXNHTFJVDZ-UHFFFAOYSA-N 1-[(6-ethoxypyridin-3-yl)methyl]-3-phenylpyrazole-4-carboxylic acid Chemical compound CCOc1ccc(Cn2cc(C(O)=O)c(n2)-c2ccccc2)cn1 HOSLEXNHTFJVDZ-UHFFFAOYSA-N 0.000 description 3
- YVHILFHKFQUXGU-UHFFFAOYSA-N 1-[(6-fluoropyridin-3-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound OC(=O)c1cn(Cc2ccc(F)nc2)nc1C(F)(F)F YVHILFHKFQUXGU-UHFFFAOYSA-N 0.000 description 3
- VETNGRMKXQEHTJ-UHFFFAOYSA-N 1-[(6-pyrrolidin-1-ylpyridin-3-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound OC(=O)c1cn(Cc2ccc(nc2)N2CCCC2)nc1C(F)(F)F VETNGRMKXQEHTJ-UHFFFAOYSA-N 0.000 description 3
- XIBBOSJKLUSJNI-UHFFFAOYSA-N 1-[[4-(azidomethyl)phenyl]methyl]pyridin-2-one Chemical compound C1=CC(CN=[N+]=[N-])=CC=C1CN1C(=O)C=CC=C1 XIBBOSJKLUSJNI-UHFFFAOYSA-N 0.000 description 3
- GNQFFRYCCDZFJK-UHFFFAOYSA-N 1-[[4-(bromomethyl)phenyl]methyl]pyrazole Chemical compound BrCc1ccc(Cn2cccn2)cc1 GNQFFRYCCDZFJK-UHFFFAOYSA-N 0.000 description 3
- CAKMJEWKVRFHFN-UHFFFAOYSA-N 1-[[4-(bromomethyl)phenyl]methyl]pyridin-2-one Chemical compound BrCC1=CC=C(CN2C=CC=CC2=O)C=C1 CAKMJEWKVRFHFN-UHFFFAOYSA-N 0.000 description 3
- DJAXWXIPSFWTIZ-UHFFFAOYSA-N 1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-propan-2-ylpyrazole-4-carboxylic acid Chemical compound CC(C)c1nn(Cc2ccc(Cn3cc(C)cn3)cc2)cc1C(O)=O DJAXWXIPSFWTIZ-UHFFFAOYSA-N 0.000 description 3
- QYGFAYBSRULXIS-UHFFFAOYSA-N 1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]imidazole-4-carboxylic acid Chemical compound Cc1cnn(Cc2ccc(Cn3cnc(c3)C(O)=O)cc2)c1 QYGFAYBSRULXIS-UHFFFAOYSA-N 0.000 description 3
- SMRYRITUCGAKLV-UHFFFAOYSA-N 1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound Cc1cnn(Cc2ccc(Cn3cc(cn3)C(O)=O)cc2)c1 SMRYRITUCGAKLV-UHFFFAOYSA-N 0.000 description 3
- NEXODGJSUADZBM-UHFFFAOYSA-N 1-amino-2-[(2,4-dimethoxyphenyl)methyl]-1H-isoquinoline-6-carbonitrile Chemical compound COc1ccc(CN2C=Cc3cc(ccc3C2N)C#N)c(OC)c1 NEXODGJSUADZBM-UHFFFAOYSA-N 0.000 description 3
- XTRZAMHRBLYOLB-UHFFFAOYSA-N 1-aminoisoquinoline-6-carbonitrile Chemical compound Nc1nccc2cc(ccc12)C#N XTRZAMHRBLYOLB-UHFFFAOYSA-N 0.000 description 3
- HDIHRESJULZUPH-UHFFFAOYSA-N 1-ethyl-4-methyl-5-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrrole-2-carboxylic acid Chemical compound CCn1c(Cc2ccc(Cn3ccccc3=O)cc2)c(C)cc1C(O)=O HDIHRESJULZUPH-UHFFFAOYSA-N 0.000 description 3
- SYNJVRVUCJMRNN-UHFFFAOYSA-N 1-tert-butyl-4,6-dimethylpyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC(C)=C2C(C#N)=CN(C(C)(C)C)C2=N1 SYNJVRVUCJMRNN-UHFFFAOYSA-N 0.000 description 3
- MJCHTYLRKNLUNO-UHFFFAOYSA-N 2,5-dimethyl-1-[(2-phenyl-1,3-thiazol-4-yl)methyl]pyrrole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=C(C)N1CC1=CSC(C=2C=CC=CC=2)=N1 MJCHTYLRKNLUNO-UHFFFAOYSA-N 0.000 description 3
- BIMDRPVEBSIHLL-UHFFFAOYSA-N 2,5-dimethyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrrole-3-carboxylic acid Chemical compound Cc1cnn(Cc2ccc(Cn3c(C)cc(C(O)=O)c3C)cc2)c1 BIMDRPVEBSIHLL-UHFFFAOYSA-N 0.000 description 3
- FPOTZUITYWJRDL-UHFFFAOYSA-N 2-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-5-oxo-1H-pyrazole-4-carboxylic acid Chemical compound Cc1cnn(Cc2ccc(Cn3cc(C(O)=O)c(=O)[nH]3)cc2)c1 FPOTZUITYWJRDL-UHFFFAOYSA-N 0.000 description 3
- TUWMKPVJGGWGNL-UHFFFAOYSA-N 3-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl]-6-(cyclopropylmethylcarbamoyl)pyridine-2-carboxylic acid Chemical compound C1=C(C=C)C(OC)=CC(C=2C(=NC(=CC=2)C(=O)NCC2CC2)C(O)=O)=C1C(=O)NC1=CC=C(C(N)=N)C=C1 TUWMKPVJGGWGNL-UHFFFAOYSA-N 0.000 description 3
- GZNSMMLOJXTLDF-UHFFFAOYSA-N 3-amino-1-[(6-ethoxypyridin-3-yl)methyl]pyrazole-4-carboxylic acid Chemical compound CCOc1ccc(Cn2cc(C(O)=O)c(N)n2)cn1 GZNSMMLOJXTLDF-UHFFFAOYSA-N 0.000 description 3
- SJNHTTIVILXPDP-UHFFFAOYSA-N 3-amino-1-[[4-(pyrazol-1-ylmethyl)phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound Nc1nn(Cc2ccc(Cn3cccn3)cc2)cc1C(O)=O SJNHTTIVILXPDP-UHFFFAOYSA-N 0.000 description 3
- JILBCGKLQFTDKO-UHFFFAOYSA-N 3-cyclopropyl-1-[(5-methoxy-6-pyrrolidin-1-ylpyridin-3-yl)methyl]pyrazole-4-carboxylic acid Chemical compound COc1cc(Cn2cc(C(O)=O)c(n2)C2CC2)cnc1N1CCCC1 JILBCGKLQFTDKO-UHFFFAOYSA-N 0.000 description 3
- ZKNNHRNGQMSJBD-UHFFFAOYSA-N 4,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound Cc1nc2[nH]ccc2c(C)c1C#N ZKNNHRNGQMSJBD-UHFFFAOYSA-N 0.000 description 3
- LQZVUKMCMFSWDH-UHFFFAOYSA-N 5-(bromomethyl)-2-chloro-3-methoxypyridine Chemical compound COc1cc(CBr)cnc1Cl LQZVUKMCMFSWDH-UHFFFAOYSA-N 0.000 description 3
- IUJPAAPIEURDEZ-UHFFFAOYSA-N 5-(bromomethyl)-2-fluoropyridine Chemical compound FC1=CC=C(CBr)C=N1 IUJPAAPIEURDEZ-UHFFFAOYSA-N 0.000 description 3
- RGQRWLOSJJOTBH-UHFFFAOYSA-N 5-bromo-1-tert-butyl-4,6-dimethylpyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1nc2n(cc(C#N)c2c(C)c1Br)C(C)(C)C RGQRWLOSJJOTBH-UHFFFAOYSA-N 0.000 description 3
- MJDCLAWSVBUKNW-UHFFFAOYSA-N 5-bromo-4,6-dimethyl-1H-pyrrolo[2,3-b]pyridine Chemical compound Cc1nc2[nH]ccc2c(C)c1Br MJDCLAWSVBUKNW-UHFFFAOYSA-N 0.000 description 3
- GPDSXWIXMALBNU-UHFFFAOYSA-N 5-bromo-4,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1nc2[nH]cc(C#N)c2c(C)c1Br GPDSXWIXMALBNU-UHFFFAOYSA-N 0.000 description 3
- PMZKIGBJJTZXKW-UHFFFAOYSA-N 6-methyl-1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound C1=C(C#N)C(C)=NC2=C1C=CN2 PMZKIGBJJTZXKW-UHFFFAOYSA-N 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 3
- 102000001399 Kallikrein Human genes 0.000 description 3
- 108060005987 Kallikrein Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- ADLULGOPZPFWPA-UHFFFAOYSA-N [4-(pyrazol-1-ylmethyl)phenyl]methanol Chemical compound C1=CC(CO)=CC=C1CN1N=CC=C1 ADLULGOPZPFWPA-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 108010011867 ecallantide Proteins 0.000 description 3
- DDMPAJQJZCYVIJ-UHFFFAOYSA-N ethyl 1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]triazole-4-carboxylate Chemical compound N1=NC(C(=O)OCC)=CN1CC(C=C1)=CC=C1CN1C(=O)C=CC=C1 DDMPAJQJZCYVIJ-UHFFFAOYSA-N 0.000 description 3
- IKGNTOGSYXYGAF-UHFFFAOYSA-N ethyl 1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]imidazole-4-carboxylate Chemical compound CCOC(=O)C1=CN(CC2=CC=C(CN3C=C(C)C=N3)C=C2)C=N1 IKGNTOGSYXYGAF-UHFFFAOYSA-N 0.000 description 3
- BQGBEOGBLKODPL-UHFFFAOYSA-N ethyl 1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cnn(Cc2ccc(Cn3cc(C)cn3)cc2)c1 BQGBEOGBLKODPL-UHFFFAOYSA-N 0.000 description 3
- DFNRXSUQAZFNCA-UHFFFAOYSA-N ethyl 1-ethyl-4-methyl-5-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrrole-2-carboxylate Chemical compound C(C)N1C(=CC(=C1CC1=CC=C(C=C1)CN1C(C=CC=C1)=O)C)C(=O)OCC DFNRXSUQAZFNCA-UHFFFAOYSA-N 0.000 description 3
- OWTSZPQRTHJAML-UHFFFAOYSA-N ethyl 1-ethyl-4-methylpyrrole-2-carboxylate Chemical compound CCOC(=O)C1=CC(C)=CN1CC OWTSZPQRTHJAML-UHFFFAOYSA-N 0.000 description 3
- WTWAMTDTWAHLRC-UHFFFAOYSA-N ethyl 2-[(4-bromophenyl)methyl]-4-methyl-1,3-thiazole-5-carboxylate Chemical compound CC1=C(C(=O)OCC)SC(CC=2C=CC(Br)=CC=2)=N1 WTWAMTDTWAHLRC-UHFFFAOYSA-N 0.000 description 3
- WANUOLLLVOSMFL-UHFFFAOYSA-N ethyl 2-acetyl-4-oxopentanoate Chemical compound CCOC(=O)C(C(C)=O)CC(C)=O WANUOLLLVOSMFL-UHFFFAOYSA-N 0.000 description 3
- CCDGWCWOZVZGLG-UHFFFAOYSA-N ethyl 3-amino-1-[(6-fluoropyridin-3-yl)methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(F)nc2)nc1N CCDGWCWOZVZGLG-UHFFFAOYSA-N 0.000 description 3
- JIYYVVUPXBPSFC-UHFFFAOYSA-N ethyl 3-amino-1-[[4-(pyrazol-1-ylmethyl)phenyl]methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(Cn3cccn3)cc2)nc1N JIYYVVUPXBPSFC-UHFFFAOYSA-N 0.000 description 3
- DHHHYQHBNBNLMP-UHFFFAOYSA-N ethyl 3-bromo-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(Cn3cc(C)cn3)cc2)nc1Br DHHHYQHBNBNLMP-UHFFFAOYSA-N 0.000 description 3
- ZLRQUYCCMANPED-UHFFFAOYSA-N ethyl 3-cyclopropyl-1-[(5-methoxy-6-pyrrolidin-1-ylpyridin-3-yl)methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2cnc(N3CCCC3)c(OC)c2)nc1C1CC1 ZLRQUYCCMANPED-UHFFFAOYSA-N 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- VBGWSQKGUZHFPS-VGMMZINCSA-N kalbitor Chemical compound C([C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)NCC(=O)NCC(=O)N[C@H]3CSSC[C@H](NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC3=O)CSSC2)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)[C@@H](C)CC)[C@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 VBGWSQKGUZHFPS-VGMMZINCSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- URCKKASOEPCAIT-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-propan-2-ylpyrazole-4-carboxamide Chemical compound C1=C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)C(C(C)C)=NN1CC(C=C1)=CC=C1CN1C=C(C)C=N1 URCKKASOEPCAIT-UHFFFAOYSA-N 0.000 description 3
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000003001 serine protease inhibitor Substances 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- JNOTXUNJEYLUMC-UHFFFAOYSA-N tert-butyl N-[(1-aminoisoquinolin-6-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCc1ccc2c(N)nccc2c1 JNOTXUNJEYLUMC-UHFFFAOYSA-N 0.000 description 3
- JASJYPPOZLVJRG-UHFFFAOYSA-N tert-butyl N-[(4,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl]carbamate Chemical compound Cc1nc2[nH]ccc2c(C)c1CNC(=O)OC(C)(C)C JASJYPPOZLVJRG-UHFFFAOYSA-N 0.000 description 3
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- WECDIFWKJQFNDV-UHFFFAOYSA-N 1-[[4-(bromomethyl)phenyl]methyl]-4-methylpyrazole Chemical compound Cc1cnn(Cc2ccc(CBr)cc2)c1 WECDIFWKJQFNDV-UHFFFAOYSA-N 0.000 description 2
- HUANEBPXWCSZDB-UHFFFAOYSA-N 1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]triazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1CC(C=C1)=CC=C1CN1C(=O)C=CC=C1 HUANEBPXWCSZDB-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- AOSOZARHUJMBLZ-UHFFFAOYSA-N 2-fluoro-5-methylpyridine Chemical compound CC1=CC=C(F)N=C1 AOSOZARHUJMBLZ-UHFFFAOYSA-N 0.000 description 2
- MJOIQWOIQBRZFK-UHFFFAOYSA-N 3-cyclopropyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound Cc1cnn(Cc2ccc(Cn3cc(C(O)=O)c(n3)C3CC3)cc2)c1 MJOIQWOIQBRZFK-UHFFFAOYSA-N 0.000 description 2
- VDDUJAHUJNRYQR-UHFFFAOYSA-N 3-methyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound Cc1cnn(Cc2ccc(Cn3cc(C(O)=O)c(C)n3)cc2)c1 VDDUJAHUJNRYQR-UHFFFAOYSA-N 0.000 description 2
- TZNIAXGPXNSFQW-UHFFFAOYSA-N 4-methyl-2-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-1,3-thiazole-5-carboxylic acid Chemical compound Cc1cnn(Cc2ccc(Cc3nc(C)c(s3)C(O)=O)cc2)c1 TZNIAXGPXNSFQW-UHFFFAOYSA-N 0.000 description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 2
- GCFGVEJJDJWWBE-UHFFFAOYSA-N 6-amino-2-methyl-5-(2-trimethylsilylethynyl)pyridine-3-carbonitrile Chemical compound Cc1nc(N)c(cc1C#N)C#C[Si](C)(C)C GCFGVEJJDJWWBE-UHFFFAOYSA-N 0.000 description 2
- SSXLCWOFGMREEF-UHFFFAOYSA-N 6-amino-5-iodo-2-methylpyridine-3-carbonitrile Chemical compound CC1=NC(N)=C(I)C=C1C#N SSXLCWOFGMREEF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CPPSSZRDGQAONC-UHFFFAOYSA-N Cc1nc2[nH]ccc2cc1CNC(=O)OC(C)(C)C Chemical compound Cc1nc2[nH]ccc2cc1CNC(=O)OC(C)(C)C CPPSSZRDGQAONC-UHFFFAOYSA-N 0.000 description 2
- 108010071241 Factor XIIa Proteins 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 2
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 description 2
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229940122920 Kallikrein inhibitor Drugs 0.000 description 2
- 102100023012 Kallistatin Human genes 0.000 description 2
- 108010077861 Kininogens Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- PFBRPHMNEWQQDW-UHFFFAOYSA-N N-acetyl-N-[5-cyano-6-methyl-3-(2-trimethylsilylethynyl)pyridin-2-yl]acetamide Chemical compound CC(=O)N(C(C)=O)c1nc(C)c(cc1C#C[Si](C)(C)C)C#N PFBRPHMNEWQQDW-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100034869 Plasma kallikrein Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000037486 Postoperative Hemorrhage Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical class C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- MTQSLOCRJVMHDI-UHFFFAOYSA-N [4-[(4-methylpyrazol-1-yl)methyl]phenyl]methylhydrazine Chemical compound Cc1cnn(Cc2ccc(CNN)cc2)c1 MTQSLOCRJVMHDI-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001409 amidines Chemical group 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001743 benzylic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229940009550 c1 esterase inhibitor Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- NVVXJVMOIGXUGC-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane;2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 NVVXJVMOIGXUGC-UHFFFAOYSA-M 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 2
- 229920006237 degradable polymer Polymers 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960001174 ecallantide Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- ARLXJAMIFBLELR-CSKARUKUSA-N ethyl (E)-2-(cyclobutanecarbonyl)-3-(dimethylamino)prop-2-enoate Chemical compound CCOC(=O)C(=C\N(C)C)\C(=O)C1CCC1 ARLXJAMIFBLELR-CSKARUKUSA-N 0.000 description 2
- JKBZYJVZIBWAKC-UHFFFAOYSA-N ethyl 1-[(6-chloro-5-methoxypyridin-3-yl)methyl]-3-cyclopropylpyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2cnc(Cl)c(OC)c2)nc1C1CC1 JKBZYJVZIBWAKC-UHFFFAOYSA-N 0.000 description 2
- HFNZNWKTYCYXTB-UHFFFAOYSA-N ethyl 1-[(6-fluoropyridin-3-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(F)nc2)nc1C(F)(F)F HFNZNWKTYCYXTB-UHFFFAOYSA-N 0.000 description 2
- LSCSOCOVTDUBRW-UHFFFAOYSA-N ethyl 1-[(6-fluoropyridin-3-yl)methyl]-3-phenylpyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(F)nc2)nc1-c1ccccc1 LSCSOCOVTDUBRW-UHFFFAOYSA-N 0.000 description 2
- MUINCVGSXOAIBG-UHFFFAOYSA-N ethyl 1-[[4-(chloromethyl)phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(CCl)cc2)nc1C(F)(F)F MUINCVGSXOAIBG-UHFFFAOYSA-N 0.000 description 2
- VYUCUPFRSYMFSI-UHFFFAOYSA-N ethyl 1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1C(F)(F)F VYUCUPFRSYMFSI-UHFFFAOYSA-N 0.000 description 2
- IZQRPPNQGXVUCC-UHFFFAOYSA-N ethyl 1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC(C=C1)=CC=C1CN1C(=O)C=CC=C1 IZQRPPNQGXVUCC-UHFFFAOYSA-N 0.000 description 2
- QVHWIHGLGPQRRA-UHFFFAOYSA-N ethyl 1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-morpholin-4-ylpyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(Cn3cc(C)cn3)cc2)nc1N1CCOCC1 QVHWIHGLGPQRRA-UHFFFAOYSA-N 0.000 description 2
- YSIUGBWGAQSQDP-UHFFFAOYSA-N ethyl 1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-propan-2-ylpyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(Cn3cc(C)cn3)cc2)nc1C(C)C YSIUGBWGAQSQDP-UHFFFAOYSA-N 0.000 description 2
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 2
- MVGVFJMXPXJRCC-UHFFFAOYSA-N ethyl 2-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-5-oxo-1H-pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(Cn3cc(C)cn3)cc2)[nH]c1=O MVGVFJMXPXJRCC-UHFFFAOYSA-N 0.000 description 2
- HPWCNBLQTVWLOH-UHFFFAOYSA-N ethyl 3-methyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(Cn3cc(C)cn3)cc2)nc1C HPWCNBLQTVWLOH-UHFFFAOYSA-N 0.000 description 2
- NDQKLXCRFMJBIM-UHFFFAOYSA-N ethyl 4-methyl-2-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)c1sc(Cc2ccc(Cn3cc(C)cn3)cc2)nc1C NDQKLXCRFMJBIM-UHFFFAOYSA-N 0.000 description 2
- VYXIHSAEOXPAEY-UHFFFAOYSA-N ethyl 5-(trifluoromethyl)-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1C(F)(F)F VYXIHSAEOXPAEY-UHFFFAOYSA-N 0.000 description 2
- VHGJLAJXZOCWKH-UHFFFAOYSA-N ethyl 5-[4-(chloromethyl)benzoyl]-1-ethyl-4-methylpyrrole-2-carboxylate Chemical compound CCOC(=O)c1cc(C)c(C(=O)c2ccc(CCl)cc2)n1CC VHGJLAJXZOCWKH-UHFFFAOYSA-N 0.000 description 2
- SYSGNTNOGOLUBN-UHFFFAOYSA-N ethyl 5-[[4-(chloromethyl)phenyl]methyl]-1-ethyl-4-methylpyrrole-2-carboxylate Chemical compound CCOC(=O)c1cc(C)c(Cc2ccc(CCl)cc2)n1CC SYSGNTNOGOLUBN-UHFFFAOYSA-N 0.000 description 2
- YPXGHKWOJXQLQU-UHFFFAOYSA-N ethyl 5-amino-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1N YPXGHKWOJXQLQU-UHFFFAOYSA-N 0.000 description 2
- HMONTLMXUZERMC-UHFFFAOYSA-N ethyl 5-bromo-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CNN=C1Br HMONTLMXUZERMC-UHFFFAOYSA-N 0.000 description 2
- HGCJVGPZFAUPOM-UHFFFAOYSA-N ethyl 5-cyclopropyl-1h-pyrazole-4-carboxylate Chemical compound C1=NNC(C2CC2)=C1C(=O)OCC HGCJVGPZFAUPOM-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- QTCSPPWTUGKKFF-UHFFFAOYSA-N methyl 2,5-dimethyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrrole-3-carboxylate Chemical compound COC(=O)c1cc(C)n(Cc2ccc(Cn3cc(C)cn3)cc2)c1C QTCSPPWTUGKKFF-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- SLRCFYCDNOSNHM-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-1-[(6-pyrrolidin-1-ylpyridin-3-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C=1C=C2C(N)=NC=CC2=CC=1CNC(=O)C(C(=N1)C(F)(F)F)=CN1CC(C=N1)=CC=C1N1CCCC1 SLRCFYCDNOSNHM-UHFFFAOYSA-N 0.000 description 2
- MCLBVPPTLFLLSH-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]imidazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1C=C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)N=C1 MCLBVPPTLFLLSH-UHFFFAOYSA-N 0.000 description 2
- CUQLASPMTDPMRH-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-3-cyclopropyl-1-[(5-methoxy-6-pyrrolidin-1-ylpyridin-3-yl)methyl]pyrazole-4-carboxamide Chemical compound C=1N=C(N2CCCC2)C(OC)=CC=1CN(N=1)C=C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)C=1C1CC1 CUQLASPMTDPMRH-UHFFFAOYSA-N 0.000 description 2
- PXZBRJHSOLRAIJ-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-3-methyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=C(C)C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)=C1 PXZBRJHSOLRAIJ-UHFFFAOYSA-N 0.000 description 2
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 2
- 231100000822 oral exposure Toxicity 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Chemical compound OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000004291 retinal vascular dysfunctions Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229950008188 sulfamidochrysoidine Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 108010036927 trypsin-like serine protease Proteins 0.000 description 2
- 238000002096 two-dimensional nuclear Overhauser enhancement spectroscopy Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- CECNSHCELGISPL-UHFFFAOYSA-N (6-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)methanamine Chemical compound Cc1nc2[nH]ccc2cc1CN CECNSHCELGISPL-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- DCVWMMMKFZVEDP-UHFFFAOYSA-N 1-(cyclobutylmethyl)triazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1CC1CCC1 DCVWMMMKFZVEDP-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- GPNYPUQQTWUKHB-UHFFFAOYSA-N 1-[[4-[(1-ethyl-3-methylpyrrol-2-yl)methyl]phenyl]methyl]pyridin-2-one Chemical compound CCN1C=CC(=C1CC2=CC=C(C=C2)CN3C=CC=CC3=O)C GPNYPUQQTWUKHB-UHFFFAOYSA-N 0.000 description 1
- ZXQPZWDTXIOSTO-UHFFFAOYSA-N 1-[[4-[(4-cyanopyrazol-1-yl)methyl]phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound OC(=O)c1cn(Cc2ccc(Cn3cc(cn3)C#N)cc2)nc1C(F)(F)F ZXQPZWDTXIOSTO-UHFFFAOYSA-N 0.000 description 1
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical compound C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 description 1
- QIPKJJHSPMUFFY-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridin-5-ylmethanamine Chemical compound NCC1=CN=C2NC=CC2=C1 QIPKJJHSPMUFFY-UHFFFAOYSA-N 0.000 description 1
- IQHBSWJOZDDAIR-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridin-5-ylmethanamine;hydrochloride Chemical compound Cl.NCC1=CN=C2NC=CC2=C1 IQHBSWJOZDDAIR-UHFFFAOYSA-N 0.000 description 1
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical class OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 1
- YAXPTWNWOBQNPG-UHFFFAOYSA-N 2-(4-bromophenyl)ethanethioamide Chemical compound NC(=S)CC1=CC=C(Br)C=C1 YAXPTWNWOBQNPG-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- UJXAVMZSVIODSH-UHFFFAOYSA-N 2-methylbenzene-1,4-dicarbonitrile Chemical compound CC1=CC(C#N)=CC=C1C#N UJXAVMZSVIODSH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- CVLHETBAROWASE-UHFFFAOYSA-N 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-oxazole Chemical compound CC1=NOC(C)=C1B1OC(C)(C)C(C)(C)O1 CVLHETBAROWASE-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- LQGSKDNLLJIRAI-UHFFFAOYSA-N 3-[3-(2-carboxyethyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]propanoic acid Chemical compound CC1(C)N(CCC(O)=O)C(=O)N(CCC(O)=O)C1=O LQGSKDNLLJIRAI-UHFFFAOYSA-N 0.000 description 1
- RSQQMIMNYCNIAI-UHFFFAOYSA-N 3-bromo-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound BrC1=NN(C=C1C(=O)O)CC1=CC=C(C=C1)CN1N=CC(=C1)C RSQQMIMNYCNIAI-UHFFFAOYSA-N 0.000 description 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
- OITNBJHJJGMFBN-UHFFFAOYSA-N 4-(chloromethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(CCl)C=C1 OITNBJHJJGMFBN-UHFFFAOYSA-N 0.000 description 1
- RCOVTJVRTZGSBP-UHFFFAOYSA-N 4-(chloromethyl)benzoyl chloride Chemical compound ClCC1=CC=C(C(Cl)=O)C=C1 RCOVTJVRTZGSBP-UHFFFAOYSA-N 0.000 description 1
- RGTBACCSTBZIEJ-UHFFFAOYSA-N 4-[(1-aminoisoquinolin-6-yl)methylcarbamoyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-3-carboxylic acid Chemical compound NC1=NC=CC2=CC(=CC=C12)CNC(=O)C=1C(=NN(C=1)CC1=CC=C(C=C1)CN1N=CC(=C1)C)C(=O)O RGTBACCSTBZIEJ-UHFFFAOYSA-N 0.000 description 1
- OTOLXPJFSYYBLG-UHFFFAOYSA-N 4-[(1-aminoisoquinolin-6-yl)methylcarbamoyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-3-carboxylic acid hydrochloride Chemical compound Cl.Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C(O)=O)cc2)c1 OTOLXPJFSYYBLG-UHFFFAOYSA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical class CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 1
- CCTTXWPBHKJBBL-UHFFFAOYSA-N 4-methyl-1-[[4-(pyrazol-1-ylmethyl)phenyl]methyl]pyrazole Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=CC=C1 CCTTXWPBHKJBBL-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- YNYDWEIQSDFDLK-UHFFFAOYSA-N 5-acetyl-1h-pyrimidine-2,4-dione Chemical compound CC(=O)C1=CNC(=O)NC1=O YNYDWEIQSDFDLK-UHFFFAOYSA-N 0.000 description 1
- BCGCNZLBQKNUSR-UHFFFAOYSA-N 5-amino-1-[[4-(pyrazol-1-ylmethyl)phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound Nc1c(cnn1Cc1ccc(Cn2cccn2)cc1)C(O)=O BCGCNZLBQKNUSR-UHFFFAOYSA-N 0.000 description 1
- HPWLCRFUNOGQMD-UHFFFAOYSA-N 5-amino-1-tert-butylpyrrole-3-carbonitrile Chemical compound CC(C)(C)N1C=C(C#N)C=C1N HPWLCRFUNOGQMD-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- OZAIJUZOQOBQDW-UHFFFAOYSA-N 6-amino-2-methylpyridine-3-carbonitrile Chemical compound CC1=NC(N)=CC=C1C#N OZAIJUZOQOBQDW-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- NCEWNEQTXXIKEB-UHFFFAOYSA-N 7-(aminomethyl)isoquinolin-1-amine hydrochloride Chemical compound Cl.NCc1ccc2ccnc(N)c2c1 NCEWNEQTXXIKEB-UHFFFAOYSA-N 0.000 description 1
- 230000035495 ADMET Effects 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- GOFXPGJOAREUPS-UHFFFAOYSA-N CC=1C=NN(C1)CC1=CC=C(CN2NC(C=C2)=O)C=C1 Chemical compound CC=1C=NN(C1)CC1=CC=C(CN2NC(C=C2)=O)C=C1 GOFXPGJOAREUPS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DDEOCKUTAUESIZ-UHFFFAOYSA-N Cl.COc1cc(Cn2cc(C(=O)NCc3ccc4c(N)nccc4c3)c(n2)C2CC2)cnc1N1CCCC1 Chemical compound Cl.COc1cc(Cn2cc(C(=O)NCc3ccc4c(N)nccc4c3)c(n2)C2CC2)cnc1N1CCCC1 DDEOCKUTAUESIZ-UHFFFAOYSA-N 0.000 description 1
- TWWUEZZVWZIDPN-UHFFFAOYSA-N Cl.Cc1cnn(Cc2ccc(Cc3nc(C)c(s3)C(=O)NCc3ccc4c(N)nccc4c3)cc2)c1 Chemical compound Cl.Cc1cnn(Cc2ccc(Cc3nc(C)c(s3)C(=O)NCc3ccc4c(N)nccc4c3)cc2)c1 TWWUEZZVWZIDPN-UHFFFAOYSA-N 0.000 description 1
- KFBHUTZNERAMAF-UHFFFAOYSA-N Cl.Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(C)n3)cc2)c1 Chemical compound Cl.Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(C)n3)cc2)c1 KFBHUTZNERAMAF-UHFFFAOYSA-N 0.000 description 1
- RJQFJOOIYULTRV-UHFFFAOYSA-N Cl.Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C#N)cc2)c1 Chemical compound Cl.Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C#N)cc2)c1 RJQFJOOIYULTRV-UHFFFAOYSA-N 0.000 description 1
- HVYMZCAFBAAOBU-UHFFFAOYSA-N Cl.Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C3CCC3)cc2)c1 Chemical compound Cl.Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C3CCC3)cc2)c1 HVYMZCAFBAAOBU-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101100453988 Homo sapiens KLK1 gene Proteins 0.000 description 1
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 101710176219 Kallikrein-1 Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 238000000023 Kugelrohr distillation Methods 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- GGJJJNKCDQLJFW-UHFFFAOYSA-N N-(5-cyano-3-ethynyl-6-methylpyridin-2-yl)acetamide Chemical compound CC(=O)Nc1nc(C)c(cc1C#C)C#N GGJJJNKCDQLJFW-UHFFFAOYSA-N 0.000 description 1
- ABALYHLDXMBKMN-UHFFFAOYSA-N N-[(1-aminoisoquinolin-6-yl)methyl]-1-[(6-ethoxypyridin-3-yl)methyl]-3-[(2-methoxyacetyl)amino]pyrazole-4-carboxamide hydrochloride Chemical compound Cl.CCOc1ccc(Cn2cc(C(=O)NCc3ccc4c(N)nccc4c3)c(NC(=O)COC)n2)cn1 ABALYHLDXMBKMN-UHFFFAOYSA-N 0.000 description 1
- JZAMENORGXQFAK-UHFFFAOYSA-N N-[(1-aminoisoquinolin-6-yl)methyl]-1-[(6-ethoxypyridin-3-yl)methyl]-3-phenylpyrazole-4-carboxamide Chemical compound NC1=NC=CC2=CC(=CC=C12)CNC(=O)C=1C(=NN(C=1)CC=1C=NC(=CC=1)OCC)C1=CC=CC=C1 JZAMENORGXQFAK-UHFFFAOYSA-N 0.000 description 1
- DTVZAFXUAGZJML-UHFFFAOYSA-N N-[(1-aminoisoquinolin-6-yl)methyl]-1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide Chemical compound Nc1nccc2cc(CNC(=O)c3cnn(Cc4ccc(Cn5ccccc5=O)cc4)c3)ccc12 DTVZAFXUAGZJML-UHFFFAOYSA-N 0.000 description 1
- SNYCRJVRBNYPTH-UHFFFAOYSA-N N-[(1-aminoisoquinolin-6-yl)methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-propan-2-ylpyrazole-4-carboxamide hydrochloride Chemical compound Cl.CC(C)c1nn(Cc2ccc(Cn3cc(C)cn3)cc2)cc1C(=O)NCc1ccc2c(N)nccc2c1 SNYCRJVRBNYPTH-UHFFFAOYSA-N 0.000 description 1
- HVZHPVJRHJPAMD-UHFFFAOYSA-N N-[(1-aminoisoquinolin-6-yl)methyl]-3-(hydroxymethyl)-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide hydrochloride Chemical compound Cl.Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(CO)n3)cc2)c1 HVZHPVJRHJPAMD-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical class C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YJYAYQDDSDXXNM-UHFFFAOYSA-N [4-[(4-methylpyrazol-1-yl)methyl]phenyl]methylhydrazine dihydrochloride Chemical compound Cl.Cl.Cc1cnn(Cc2ccc(CNN)cc2)c1 YJYAYQDDSDXXNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- XLUXHEZIGIDTCC-UHFFFAOYSA-N acetonitrile;ethyl acetate Chemical compound CC#N.CCOC(C)=O XLUXHEZIGIDTCC-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 1
- 239000003152 bradykinin antagonist Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000013132 cardiothoracic surgery Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- FINPLSBBDVRBPA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane;2-methoxy-2-methylpropane;2-phenylethanamine Chemical compound [Pd+]Cl.COC(C)(C)C.NCCC1=CC=CC=[C-]1.CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 FINPLSBBDVRBPA-UHFFFAOYSA-M 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007256 debromination reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- GODHNXFEWMTMTC-UHFFFAOYSA-N ethyl 1-[[4-(chloromethyl)phenyl]methyl]-5-(trifluoromethyl)pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cnn(Cc2ccc(CCl)cc2)c1C(F)(F)F GODHNXFEWMTMTC-UHFFFAOYSA-N 0.000 description 1
- KLWYPRNPRNPORS-UHFFFAOYSA-N ethyl 1h-imidazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=CN1 KLWYPRNPRNPORS-UHFFFAOYSA-N 0.000 description 1
- RDULEYWUGKOCMR-UHFFFAOYSA-N ethyl 2-chloro-3-oxobutanoate Chemical compound CCOC(=O)C(Cl)C(C)=O RDULEYWUGKOCMR-UHFFFAOYSA-N 0.000 description 1
- JCTFXFTXAYKTAV-UHFFFAOYSA-N ethyl 3-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(Cn3cc(C)cn3)cc2)nc1-c1c(C)noc1C JCTFXFTXAYKTAV-UHFFFAOYSA-N 0.000 description 1
- ANSORWIOTJMVHC-UHFFFAOYSA-N ethyl 3-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]imidazole-4-carboxylate Chemical compound CCOC(=O)c1cncn1Cc1ccc(Cn2cc(C)cn2)cc1 ANSORWIOTJMVHC-UHFFFAOYSA-N 0.000 description 1
- DUGJTWQYWLKUBN-UHFFFAOYSA-N ethyl 3-cyano-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(Cn3cc(C)cn3)cc2)nc1C#N DUGJTWQYWLKUBN-UHFFFAOYSA-N 0.000 description 1
- HYHZQZSNOAJEPU-UHFFFAOYSA-N ethyl 3-cyclobutyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1CCC1 HYHZQZSNOAJEPU-UHFFFAOYSA-N 0.000 description 1
- ASXKVRAVGLGAGY-UHFFFAOYSA-N ethyl 3-cyclopropyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cn(Cc2ccc(Cn3cc(C)cn3)cc2)nc1C1CC1 ASXKVRAVGLGAGY-UHFFFAOYSA-N 0.000 description 1
- JDPRRECMRPCSIF-UHFFFAOYSA-N ethyl 3-oxobutanoate;sodium Chemical compound [Na].CCOC(=O)CC(C)=O JDPRRECMRPCSIF-UHFFFAOYSA-N 0.000 description 1
- FDOKNRFUGXEHEE-UHFFFAOYSA-N ethyl 5-[[4-(chloromethyl)phenyl]-hydroxymethyl]-1-ethyl-4-methylpyrrole-2-carboxylate Chemical compound CCOC(=O)c1cc(C)c(C(O)c2ccc(CCl)cc2)n1CC FDOKNRFUGXEHEE-UHFFFAOYSA-N 0.000 description 1
- IUPWWPTWMVQQAQ-UHFFFAOYSA-N ethyl 5-amino-1-[(6-fluoropyridin-3-yl)methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cnn(Cc2ccc(F)nc2)c1N IUPWWPTWMVQQAQ-UHFFFAOYSA-N 0.000 description 1
- UFEWLZNLFJRADQ-UHFFFAOYSA-N ethyl 5-bromo-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxylate Chemical compound CCOC(=O)c1cnn(Cc2ccc(Cn3cc(C)cn3)cc2)c1Br UFEWLZNLFJRADQ-UHFFFAOYSA-N 0.000 description 1
- YIDCXWARXKWUME-UHFFFAOYSA-N ethyl 5-cyclobutyl-1H-pyrazole-4-carboxylate Chemical compound CCOC(=O)c1c[nH]nc1C1CCC1 YIDCXWARXKWUME-UHFFFAOYSA-N 0.000 description 1
- LQIYWOVORITWEA-UHFFFAOYSA-N ethyl 5-phenyl-1h-pyrazole-4-carboxylate Chemical compound C1=NNC(C=2C=CC=CC=2)=C1C(=O)OCC LQIYWOVORITWEA-UHFFFAOYSA-N 0.000 description 1
- CBQOEYAQFVRTNV-UHFFFAOYSA-N ethyl 5-propan-2-yl-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CNN=C1C(C)C CBQOEYAQFVRTNV-UHFFFAOYSA-N 0.000 description 1
- FDLDWKIEWAWOSL-UHFFFAOYSA-N ethyl acetate;2-methylpentane Chemical compound CCCC(C)C.CCOC(C)=O FDLDWKIEWAWOSL-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007478 fluorogenic assay Methods 0.000 description 1
- 229960004285 fomepizole Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229940039088 kininogenase Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- OQWZEJIISPYZPW-UHFFFAOYSA-N methyl 2,5-dimethyl-1H-pyrrole-3-carboxylate Chemical compound COC(=O)C=1C=C(C)NC=1C OQWZEJIISPYZPW-UHFFFAOYSA-N 0.000 description 1
- XPHMEWSKODAWPT-UHFFFAOYSA-N methyl 6-chloro-5-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C(OC)=C1 XPHMEWSKODAWPT-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 1
- GGVYRGRBULRJBJ-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-1-[(6-ethoxy-5-fluoropyridin-3-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C1=C(F)C(OCC)=NC=C1CN1N=C(C(F)(F)F)C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)=C1 GGVYRGRBULRJBJ-UHFFFAOYSA-N 0.000 description 1
- GKPBRBZRCXWGEQ-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-1-[(6-ethoxypyridin-3-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C1=NC(OCC)=CC=C1CN1N=C(C(F)(F)F)C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)=C1 GKPBRBZRCXWGEQ-UHFFFAOYSA-N 0.000 description 1
- DWFRBDIXHQEHJF-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-1-[(6-propoxypyridin-3-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C1=NC(OCCC)=CC=C1CN1N=C(C(F)(F)F)C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)=C1 DWFRBDIXHQEHJF-UHFFFAOYSA-N 0.000 description 1
- VRYHLJFFMXJWLQ-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-1-[[4-(pyrazol-1-ylmethyl)phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C=1C=C2C(N)=NC=CC2=CC=1CNC(=O)C(C(=N1)C(F)(F)F)=CN1CC(C=C1)=CC=C1CN1C=CC=N1 VRYHLJFFMXJWLQ-UHFFFAOYSA-N 0.000 description 1
- NWLUWTWQKQUQDZ-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-1-[[4-[(4-carbamoylpyrazol-1-yl)methyl]phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C1=C(C(=O)N)C=NN1CC(C=C1)=CC=C1CN1N=C(C(F)(F)F)C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)=C1 NWLUWTWQKQUQDZ-UHFFFAOYSA-N 0.000 description 1
- HXLUIKPALDGUQR-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=C(C(F)(F)F)C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)=C1 HXLUIKPALDGUQR-UHFFFAOYSA-N 0.000 description 1
- DWHBFTOTOHZYPK-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-morpholin-4-ylpyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=C(N2CCOCC2)C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)=C1 DWHBFTOTOHZYPK-UHFFFAOYSA-N 0.000 description 1
- OUIUBQFLHJFGIC-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-2,5-dimethyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrrole-3-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1C(C)=C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)C=C1C OUIUBQFLHJFGIC-UHFFFAOYSA-N 0.000 description 1
- VMIWCYSSHRTVOL-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-3-(hydroxymethyl)-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=C(CO)C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)=C1 VMIWCYSSHRTVOL-UHFFFAOYSA-N 0.000 description 1
- XRSMOUUDULMQKD-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-3-(methoxymethyl)-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide Chemical compound C1=C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)C(COC)=NN1CC(C=C1)=CC=C1CN1C=C(C)C=N1 XRSMOUUDULMQKD-UHFFFAOYSA-N 0.000 description 1
- VUTOLLLOTRHDTA-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-3-cyclobutyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=C(C2CCC2)C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)=C1 VUTOLLLOTRHDTA-UHFFFAOYSA-N 0.000 description 1
- UAXGFNOVXFRLLA-UHFFFAOYSA-N n-[(1-aminoisoquinolin-6-yl)methyl]-4-methyl-2-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-1,3-thiazole-5-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CC1=NC(C)=C(C(=O)NCC=2C=C3C=CN=C(N)C3=CC=2)S1 UAXGFNOVXFRLLA-UHFFFAOYSA-N 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000012041 precatalyst Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004268 retinal thickening Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- YKLJDMCXKMIXBD-UHFFFAOYSA-M sodium;3-(2-dicyclohexylphosphanylphenyl)-2,4-dimethoxybenzenesulfonate Chemical compound [Na+].COC1=CC=C(S([O-])(=O)=O)C(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 YKLJDMCXKMIXBD-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003458 sulfonic acid derivatives Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZAWXZPIICPRCHA-UHFFFAOYSA-N tert-butyl N-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methylamino]carbamate Chemical compound Cc1cnn(Cc2ccc(CNNC(=O)OC(C)(C)C)cc2)c1 ZAWXZPIICPRCHA-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826596P | 2013-05-23 | 2013-05-23 | |
| US201361865756P | 2013-08-14 | 2013-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2909885T3 true ES2909885T3 (es) | 2022-05-10 |
Family
ID=50841878
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17166782T Active ES2909885T3 (es) | 2013-05-23 | 2014-05-23 | Inhibidores de la calicreína plasmática |
| ES14727034.2T Active ES2626968T3 (es) | 2013-05-23 | 2014-05-23 | Derivados heterocíclicos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14727034.2T Active ES2626968T3 (es) | 2013-05-23 | 2014-05-23 | Derivados heterocíclicos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9533987B2 (enExample) |
| EP (2) | EP2999697B1 (enExample) |
| JP (1) | JP6538028B2 (enExample) |
| KR (1) | KR102276700B1 (enExample) |
| CN (1) | CN105452240B (enExample) |
| AU (1) | AU2014270152B9 (enExample) |
| BR (1) | BR112015028879B1 (enExample) |
| CA (1) | CA2912285C (enExample) |
| CL (1) | CL2015003442A1 (enExample) |
| ES (2) | ES2909885T3 (enExample) |
| HU (2) | HUE057851T2 (enExample) |
| IL (1) | IL242513A0 (enExample) |
| MX (1) | MX363689B (enExample) |
| MY (1) | MY174018A (enExample) |
| PH (1) | PH12015502549A1 (enExample) |
| PL (2) | PL3305778T3 (enExample) |
| PT (1) | PT3305778T (enExample) |
| RU (1) | RU2712621C2 (enExample) |
| SG (1) | SG11201509303WA (enExample) |
| SI (1) | SI3305778T1 (enExample) |
| WO (1) | WO2014188211A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| JP6527147B2 (ja) * | 2013-08-14 | 2019-06-05 | カルヴィスタ ファーマシューティカルズ リミテッド | 血漿カリクレインの阻害薬 |
| US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| EA032713B1 (ru) | 2013-12-30 | 2019-07-31 | Лайфсай Фармасьютикалс, Инк. | Терапевтические ингибирующие соединения |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421088D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| CN104530013B (zh) * | 2014-12-04 | 2016-06-29 | 中国农业大学 | 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途 |
| CN104761491B (zh) * | 2015-03-31 | 2018-08-21 | 山东友帮生化科技有限公司 | 2-氨基-3-碘-5-溴吡啶的合成方法 |
| KR20180030545A (ko) * | 2015-06-22 | 2018-03-23 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 바이사이클릭 헤테로사이클릭 아미드 유도체 |
| US10640486B2 (en) | 2015-10-27 | 2020-05-05 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| JP6917988B2 (ja) * | 2015-10-27 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
| GB201609519D0 (en) * | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
| JP6884801B2 (ja) | 2016-05-31 | 2021-06-09 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレインインヒビターとしてのピラゾール誘導体 |
| GB201609603D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| US10501440B2 (en) | 2017-04-21 | 2019-12-10 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| MX2020005168A (es) | 2017-11-29 | 2020-08-20 | Kalvista Pharmaceuticals Ltd | Formas de dosificacion que contienen un inhibidor calicreina de plasma. |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| US10695334B2 (en) | 2018-08-16 | 2020-06-30 | Boehringer Ingelheim International Gmbh | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
| CN112839711A (zh) | 2018-10-10 | 2021-05-25 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的苯基四唑衍生物 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021032935A1 (en) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
| TW202535863A (zh) | 2020-02-13 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| WO2021175290A1 (zh) * | 2020-03-04 | 2021-09-10 | 南京明德新药研发有限公司 | 杂环类化合物 |
| WO2022079446A1 (en) | 2020-10-15 | 2022-04-21 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| WO2022084693A1 (en) | 2020-10-23 | 2022-04-28 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| WO2022172006A1 (en) | 2021-02-09 | 2022-08-18 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
| WO2023002219A1 (en) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
| WO2023185634A1 (zh) * | 2022-03-30 | 2023-10-05 | 南京明德新药研发有限公司 | 作为血浆激肽释放酶抑制剂的杂环类化合物 |
| JP2025514861A (ja) | 2022-04-27 | 2025-05-09 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレイン阻害剤の製剤 |
| WO2024180100A1 (en) | 2023-02-27 | 2024-09-06 | Kalvista Pharmaceuticals Limited | New solid form of a plasma kallikrein inhibitor |
| WO2025153806A1 (en) | 2024-01-15 | 2025-07-24 | Kalvista Pharmaceuticals Limited | Methods for determining amidolytic activity |
| WO2025172693A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2025172692A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| IL123986A (en) | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
| ID30460A (id) * | 1999-04-15 | 2001-12-06 | Bristol Myers Squibb Co | Inhibitor-inhibitor protein siklik tirosin kinase |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| EP2281885A1 (en) | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| US7429604B2 (en) * | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| WO2008016883A2 (en) * | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| MX2012006913A (es) * | 2009-12-18 | 2012-08-23 | Activesite Pharmaceuticals Inc | Profarmacos de inhibidores de calicreina plasmatica. |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| WO2012004678A2 (en) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
| US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| EP2697196A1 (en) * | 2011-04-13 | 2014-02-19 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| US20140378474A1 (en) * | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| WO2013130603A1 (en) * | 2012-02-27 | 2013-09-06 | Board Of Regents, The University Of Texas System | Ganglioside gd2 as a marker and target on cancer stem cells |
-
2014
- 2014-05-23 CN CN201480037390.8A patent/CN105452240B/zh not_active Expired - Fee Related
- 2014-05-23 HU HUE17166782A patent/HUE057851T2/hu unknown
- 2014-05-23 ES ES17166782T patent/ES2909885T3/es active Active
- 2014-05-23 CA CA2912285A patent/CA2912285C/en active Active
- 2014-05-23 SI SI201431947T patent/SI3305778T1/sl unknown
- 2014-05-23 PL PL17166782T patent/PL3305778T3/pl unknown
- 2014-05-23 PT PT171667827T patent/PT3305778T/pt unknown
- 2014-05-23 PL PL14727034T patent/PL2999697T3/pl unknown
- 2014-05-23 SG SG11201509303WA patent/SG11201509303WA/en unknown
- 2014-05-23 BR BR112015028879-0A patent/BR112015028879B1/pt not_active IP Right Cessation
- 2014-05-23 MY MYPI2015704237A patent/MY174018A/en unknown
- 2014-05-23 JP JP2016514486A patent/JP6538028B2/ja not_active Expired - Fee Related
- 2014-05-23 WO PCT/GB2014/051592 patent/WO2014188211A1/en not_active Ceased
- 2014-05-23 KR KR1020157036257A patent/KR102276700B1/ko not_active Expired - Fee Related
- 2014-05-23 US US14/892,055 patent/US9533987B2/en not_active Expired - Fee Related
- 2014-05-23 EP EP14727034.2A patent/EP2999697B1/en active Active
- 2014-05-23 AU AU2014270152A patent/AU2014270152B9/en not_active Ceased
- 2014-05-23 RU RU2015154987A patent/RU2712621C2/ru active
- 2014-05-23 MX MX2015016085A patent/MX363689B/es unknown
- 2014-05-23 EP EP17166782.7A patent/EP3305778B1/en active Active
- 2014-05-23 ES ES14727034.2T patent/ES2626968T3/es active Active
- 2014-05-23 HU HUE14727034A patent/HUE034829T2/en unknown
-
2015
- 2015-11-06 PH PH12015502549A patent/PH12015502549A1/en unknown
- 2015-11-09 IL IL242513A patent/IL242513A0/en active IP Right Grant
- 2015-11-23 CL CL2015003442A patent/CL2015003442A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2909885T3 (es) | Inhibidores de la calicreína plasmática | |
| US11001578B2 (en) | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | |
| ES2908585T3 (es) | Compuestos de N-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de la calicreína plasmática | |
| ES2691084T3 (es) | Inhibidores bicíclicos de plasma calicreína | |
| BR112015016293B1 (pt) | Derivados de benzilamina, seus usos, e composição farmacêutica | |
| TWI636047B (zh) | 雜環衍生物 | |
| HK1253870B (en) | Inhibitors of plasma kallikrein | |
| HK1253870A1 (en) | Inhibitors of plasma kallikrein | |
| HK1221218B (en) | Heterocyclic derivates | |
| HK40016863B (en) | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | |
| HK40016863A (en) | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | |
| BR122020026459B1 (pt) | Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática, seus usos, e composição farmacêutica | |
| NZ714027B2 (en) | Heterocyclic derivates |